We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Aushon Biosystems Thrives with Increasing Demand for Personalized Medicine
News

Aushon Biosystems Thrives with Increasing Demand for Personalized Medicine

Aushon Biosystems Thrives with Increasing Demand for Personalized Medicine
News

Aushon Biosystems Thrives with Increasing Demand for Personalized Medicine

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Aushon Biosystems Thrives with Increasing Demand for Personalized Medicine"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

With a range of products and services driving the development of personalized medicine, Aushon Biosystems has appointed Thomas Mac Mahon, former president and CEO of Laboratory Corporation of America® Holdings (LabCorp®), to its board of directors. The expansion of its board builds on Aushon’s recent momentum as it is poised for significant growth in 2013.

Aushon provides a suite of multiplex immunoassay products and services for the discovery and development of the biomarkers necessary to enable personalized medicine innovation. Aushon’s multiplex approach involves simultaneously measuring and comparing multiple proteins – which eliminates the cost and time obstacles that have traditionally been associated with personalized medicine development with the singleplex ELISA platform.

“Multiplex technology allows us to cast a wider net across a diverse array of biologies known to play a role in the development of cancer and determine the response of pharmacological agents on them,” said Dr. Andrew Nixon, associate professor of medicine and director of the Phase I Biomarker Laboratory at Duke University. “Using this research approach, we’re better able to allocate our limited resources – both patient sample and money – for optimal success.”

Life sciences and diagnostics industry veteran Mac Mahon took notice of Aushon’s multiplex approach as critical to the future of personalized medicine.

“The current gold-standard approach to protein analysis comes with unnecessary cost and time barriers that prevent personalized medicine from becoming a reality for all,” said Mac Mahon. “I’m excited to continue my work advancing diagnostics and personalized medicine advancement with Aushon – which has created the approach that breaks down the current barriers – and will drive the future of personalized medicine.”

Mac Mahon served as chairman of LabCorp from 1996 to 2009 and as CEO and president from 1997 to 2006. Previously, he held the roles of senior vice president of Hoffmann-La Roche Inc., president of Roche Diagnostics Group, and chairman of PharMerica Corporation. Mac Mahon has also been presiding director of Aristotle Holding, Inc. and Express Scripts Holding Company since May 2008 and also serves as a director of SynapDx Corporation.

Advertisement